Treatment of rats with the vitamin B12 analogue hydroxy-cobalaminic-lactaml (HCCL) impairs methylmalonyl-CoA mutase function and leads to methylmalonic aciduria due to intracellular accumulation of propionyl and methylmalonyl-CoA.
Introduction
Treatment of rats with the vitamin B12 analogue hydroxy-cobalaminic-lactaml (HCCL) impairs methylmalonyl-CoA mutase function and leads to methylmalonic aciduria due to intracellular accumulation of propionyl and methylmalonyl-CoA. Since accumulation of these acyl-CoAs disrupts normal cellular regulation, the present investigation characterized metabolism in hepatocytes and liver mitochondria from rats treated subcutaneously with HCCL or saline (control) by osmotic minipump. Consistent with decreased methylmalonyl-CoA mutase activity, 14C02 production from 1-"4C-propionate (1 mM) was decreased by 76% and 82% after 2-3 wk and 5-6 wk of HCCL treatment, respectively. In contrast, after 5-6 wk of HCCL treatment, "4CO2 production from 1-"4C-pyruvate (10 mM) and 1-'4C-palmitate (0.8 mM) were increased by 45% and 49%, respectively. In isolated liver mitochondria, state 3 oxidation rates were unchanged or decreased, and activities of the mitochondrial enzymes, citrate synthetase, succinate dehydrogenase, carnitine palmitoyltransferase, and glutamate dehydrogenase (expressed per milligram mitochondrial protein) were unaffected by HCCL treatment. In contrast, activities of the same enzymes were significantly increased in both liver homogenate (expressed per gram liver) and isolated hepatocytes (expressed per 106 cells) from HCCL-treated rats. The mitochondrial protein per gram liver, calculated on the basis of the recovery of the mitochondrial enzymes, increased by 39% in 5-6 wk HCCL-treated rats. Activities of lactate dehydrogenase, catalase, cyanide-insensitive palmitoyl-CoA oxidation, and arylsulfatase A in liver were not affected by HCCL treatment. Hepatic levels of mitochondrial mRNAs were elevated up to 10-fold in HCCL-treated animals as assessed by Northern blot analysis. Thus, HCCL treatment is associated with enhanced mitochondrial oxidative capacity and an increased mitochondrial protein content per gram liver. Increased mitochondrial oxidative capacity may be a compensatory mechanism in response to the metabolic insult induced by HCCL administration. (J. Clin. Invest. 1990 . 86:2054-2061.) Key words: organic acidurias * animal model * cobalamin analogues -mitochondrial function * mitochondrial biogenesis Vitamin B 12 (cobalamin) deficiency leads to decreased activity of the cobalamin-requiring enzymes methylmalonyl-CoA mutase and methionine synthetase (1) . Decreased activity of methylmalonyl-CoA mutase results in accumulation of methylmalonyl-and propionyl-CoA, and methylmalonic aciduria (2) (3) (4) . This defect is analogous to the metabolic defect in patients with hereditary methylmalonic acidurias. The vitamin B 12-deficient rat has provided a useful animal model for the human methylmalonic acidurias and allowed the investigation of hepatic metabolism in the presence of this specific, metabolic insult (4) (5) (6) . Dietary vitamin B 12 deficiency is difficult to achieve, and the resulting metabolic defect shows a high variability between treated animals (7, 8 ). An alternative methodology to induce decreased activity of methylmalonyl-CoA mutase is treatment with hydroxy-cobalamin [c-lactam] (HCCL),' a synthetic vitamin B 12 analogue (4-6). Rats treated with HCCL develop decreased hepatic vitamin B 12 levels (4), decreased methylmalonyl-CoA mutase and methionine synthetase activity (6) , and decreased propionate metabolism with an increased renal excretion of methylmalonic acid (4) (5) (6) .
Increased hepatocellular propionyl and methylmalonylCoA concentrations inhibit several metabolic activities, including gluconeogenesis (9, 10) , urea synthesis (9, 11) fatty acid oxidation (11, 12) and pyruvate decarboxylation (13, 14) . In contrast, in rats with chronic accumulation of propionyl and methylmalonyl-CoA induced by dietary vitamin B 12 deficiency, gluconeogenetic and ketogenetic responses to fasting were intact in vivo (4), suggesting compensatory mechanisms that mitigate the toxic effects of accumulated acyl-CoAs. One compensatory mechanism in rats with dietary and functional vitamin B 12 deficiency is increased hepatic total CoA concentration (4, 15) .
To further study hepatic metabolism under conditions of impaired methylmalonyl-CoA mutase activity, hepatic mitochondrial function in HCCL-and saline-treated rats was characterized. Mitochondrial function was quantified by measurement of fuel oxidation rates in isolated hepatocytes and mitochondria. In addition, activities of mitochondrial and extramitochondrial enzymes were determined in isolated mitochondria, liver homogenates, and the hepatocyte preparations. Levels of mitochondrial RNA were determined by Northem blot analysis using as a probe whole mouse mito- 25) . After a treatment period of 2-3 wk, control animals weighed 310±20 g (n = 6) and HCCL-treated animals 300±20 g (n = 6), respectively. After 5-6 wk, control animals weighed 330±30 g (n = 6) and HCCL-treated animals 340±20 g (n = 7), respectively.
Hepatocyte isolation. Hepatocytes were prepared from fed rats by the method of Berry and Friend (16) with the modifications described previously (17). All hepatocyte preparations were started at 07:00. Isolated hepatocytes used in the current studies were 91±3% (n = 13) viable based on trypan blue exclusion, contained 3.41±0.87 mg protein/106 cells (n = 13), and had a wet weight of 16.5±3.1 mg/106 cells (n = 13). Hepatocytes from control and HCCL-treated animals did not differ with respect to any of the parameters assessed.
Hepatocyte metabolism. '4C02, and '4C-glucose formation from '4C-labeled substrates by the isolated hepatocytes were measured in 25-ml Erlenmeyer flasks equipped with sidearms and centerwells. Incubation procedures were as detailed elsewhere (18) . The incubations contained hepatocytes (2.42±0.69 X 106 cells/ml; n = 13), 1% defatted BSA (wt/vol), 124 mM NaCl, 3.8 mM KCI, 0.95 mM KH2PO4, 1.9 mM MgSO4, 0.90 mM CaCl2, 20 mM NaHCO3, 8 mM Tris(hydroxymethyl) aminomethane, 3.2 mM glucose, and other compounds as detailed in the individual experiments. The total incubation volume was 2.5 ml. The incubations were conducted under 95% 02/5% CO2 at 37°C. After a 30-min preincubation, the substrates were added at time 0. The specific activities of the substrates were individually determined for each experiment and averaged 81 dpm/nmol for 1.0 mM 1 -'4C-propionate, 22 dpm/nmol for 10.0 mM 1-'4C-propionate, 5.0 dpm/ nmol for 10.0 mM 1-'4C-pyruvate, and 110 dpm/nmol for 0.8 mM 1-'4C-palmitate. The reactions were terminated by the addition of perchloric acid to yield a final concentration of 3% (vol/vol) in the incubations.
'4C02 was collected in the flask centerwells containing 0.3 ml ethanolamine/ethylene glycol monomethyl ether (1:2, vol/vol). '4C contained in the incubations terminated at time 0 was subtracted to provide net '4C02 production. The amount of 1-'4C-substrate used for CO2 formation was calculated as '4CO2 production (net dpm) divided by the specific activity of the substrate used. For propionate, '4CO2 arising from tricarboxylic acid cycle activity was estimated by subtracting '4C-glucose from net '4C02 measured under identical conditions (18) .
For the quantification of '4C-glucose production from 1-'4C-pyruvate, aliquots were removed from the incubations at time 0 and after 30 min and added to an equal volume of cold 6% perchloric acid (vol/vol). After alkaline hydrolysis (to hydrolyze '4C-acylcarnitines) the samples were neutralized and passed through a Dowex 1 x 8 Clform mini-column (18, 19) . Net 1-'4C-substrate used for glucose production was calculated as '4C-glucose (net dpm) divided by the specific activity of the substrate.
Mitochondrial isolation and incubation. Liver mitochondria were isolated as described by Hoppel et al. (20) . Briefly, fed rats were killed by decapitation between 08:00 and 09:00 a.m. Liver weights were 3.7±0.2 and 3.3±0.2 g/100 g body weight in 2-3 wk treated control (n = 3) and HCCL-treated (n = 3) animals, respectively, and 3.3±0.2 and 3.5±0.2 g/100 g body weight in 5-6 wk treated control (n = 3) and HCCL-treated animals (n = 3), respectively. The liver was quickly exposed and a freeze-clamped sample was taken (clamps cooled in acetone/dry ice). The remainder ofthe liver was removed and placed in ice-cold MSM-buffer (220 mM mannitol, 70 mM sucrose, 5 mM MOPS; pH 7.4). The (26) . Palmitoylcarnitine hydrolase activity was determined using a blank containing no CoA and substracted to yield carnitine palmitoyltransferase activity. Catalase activity (27) , and cyanide-insensitive palmitoyl-CoA oxidation (28) were determined as peroxisomal markers, arylsulfatase A activity as a lysosomal marker (29) , and lactate dehydrogenase activity as a soluble cytoplasmatic enzyme (30). Enzyme activities are expressed as nanomoles per minute per milligram protein, per gram liver or per 106 cells with the exception of catalase, where the first order reaction constant is given. Protein concentrations were determined using the biuret method using BSA as standard (3 1).
Isolation and profiling ofmitochondrial RNA. Total RNA was isolated from liver homogenate by centrifugation on a cesium chloride gradient as described previously (32) . Purified RNA was quantified by absorbance at 260 nm, assuming an extinction coefficient of 20 ml/mg/cm. The amount of RNA isolated was not different between control and treated animals, averaging 4.5±1.1 (n = 3) and 3.9±0. 4 Mg/mg liver wet weight (n = 3) for control and 5-6 wk HCCL-treated animals, respectively. The A269/A280 ratio of the RNA (33) .
Hybridization and autoradiography were performed as described previously (32) . The membranes were then exposed to x-ray films (Kodak X-Omat AR) for autoradiography. The bands on the autoradiographs were quantified on an Ultra Scan Laser Densitometer (model 2202; LKB Instruments, Inc., Gaithersburg, MD). The relative radioactivity of each band was determined within the instrumental absorbance ranges that gave linear relationships between radioactivity and absorbance.
Reagents. I-`4C-Propionate, l-`4C-palmitate and I-`4C-pyruvate were purchased from New England Nuclear (Boston, MA). Palmitoyl-[Me-'4C]L-carnitine and palmitoyl-L-carnitine were prepared by the method of Ziegler et al. (34) , and were provided by Dr. Charles L. Hoppel (Case Western Reserve University, Cleveland, OH). Collagenase (type II) used for the isolation of hepatocytes was from Worthington Biochemical Corp. (Freehold, NJ). HCCL was prepared by the reduction of the previously synthesized cyanocobalamin analogue (35, 36) . Octanoyl-and palmitoyl-CoA, and defatted BSA were purchased from Sigma Chemical Co. (St. Louis, MO). All other chemicals used were of reagent grade.
Statistics. Data are presented as mean±standard deviation with n referring to the number of samples analyzed, each from different animals. Data were analyzed by analysis of variance (ANOVA) (37) . Student's t test with Bonferroni correction was used to compare individual means in the case of a significant Fin the ANOVA (37). Linear regression analysis was performed by the method of least squares (37) . P < 0.05 was considered to be statistically significant.
Results
Hepatocytes for metabolic studies were isolated from animals treated with saline (control) or HCCL for 2-3 wk or 5-6 wk. Consistent with previous studies (5), '4CO2 production from 1-"4C-propionate (1 mM) was decreased by 83% in hepatocytes from 5-6-wk HCCL-treated rats as compared with controls, averaging 67.4±19.4 and 11.8±1.3 nmol/106 hepatocytes/30 min (P < 0.05) for control (n = 5) and HCCL-treated animals (n = 4), respectively. In contrast, after 5-6 wk of HCCL treatment, '4C02 production rates from 1-14C-pyruvate (10 mM) were increased from 710±160 in hepatocytes from control animals (n = 6) to 1,040±150 nmol/ 106 hepatocytes/30 min (P < 0.05) in hepatocytes from HCCL-treated rats (n = 4). Similarly, hepatocyte 14C02 production rates from 1-'4C-palmitate (0.8 mM) increased (P < 0.05) from 7.0±1.9 (control animals n = 5) to 10.4±2.0 nmol/106 hepatocytes/30 min (HCCLtreated rats, n = 4). In hepatocytes from rats treated with HCCL for 2-3 wk (n = 3), 14CO2 production from I-_4C-pyruvate (10 mM) and 1-_4C-palmitate (0.8 mM) were 790±60 and 8.8±1.0 nmol/106 hepatocytes/30 min, respectively. In contrast to 14CO2 production, 14C-glucose production from 1-"4C-pyruvate was not different in hepatocytes from control animals as compared with hepatocytes from 5-6-wk HCCLtreated animals, averaging 111±27 and 135±32 nmol/106 hepatocytes/30 min in control (n = 6) and HCCL-treated animals (n = 4), respectively.
Oxidative metabolism was further characterized using isolated liver mitochondria from control and HCCL-treated rats. No difference in state 3 oxidation rates was observed between mitochondria from HCCL-treated and control animals with ,8-hydroxybutyrate as substrate. State 3 oxygen consumption expressed per milligram mitochondrial protein was reduced by 37% with palmitoyl-L-carnitine as substrate after 2-3 wk, and with pyruvate and palmitoyl-L-carnitine as substrates (by 35% and 58%, respectively) after 5-6 wk of treatment with HCCL (Table I) . Decreasing the palmitoyl-L-carnitine concentration from 80 to 40 and 20 umol/liter increased state 3 oxygen consumption by mitochondria from HCCL-treated rats by 31% and 47% (mean of two determinations), respectively. In mitochondrial incubations from control rats, lowering the palmitoyl-L-carnitine concentration had no effect on state 3 respiration. State 4 oxidation rates were equal in mitochondrial preparations from control and HCCL-treated rats (data not shown), and thus the respiratory control ratio showed the same (Table II) . However, as seen in Table  III , all four mitochondrial enzymes showed increased activity when assayed in the liver homogenate (activity expressed per gram liver) or in isolated hepatocytes (activity expressed per 106 cells). Based on the enzyme activities in the mitochondrial preparations and in the liver homogenates, the mitochondrial protein content per gram liver was calculated (Table IV) . The use of the four enzymes yielded four estimates of mitochondrial protein content per gram liver, which, when averaged, showed a 39% increase after 5-6 wk of HCCL treatment. This increase was specific for the mitochondrial compartment as activities of lactate dehydrogenase (a cytosolic enzyme), arylsulfatase A (a lysosomal enzyme), and catalase-and cyanideinsensitive palmitoyl-CoA oxidation (peroxisomal enzyme activities) were all unaffected by HCCL treatment, both in the mitochondrial fraction (data not shown) and per gram liver weight (Table V) . The rate of pyruvate oxidation by hepatocytes from HCCL-treated animals was linearly correlated with the citrate synthetase and carnitine palmitoyltransferase activities determined in the hepatocytes (Fig. 1) , demonstrating that the increased oxidation capacity reflected increased mitochondrial content per hepatocyte.
An increased mitochondrial protein content per gram liver can result from an increased synthesis and/or a reduced breakdown of mitochondrial protein.
As an index of mitochondrial biogenesis, mitochondrial RNA content was compared in livers from control and 5-6-wk HCCL-treated rats. Total RNA was extracted, resolved by agarose gel electrophoresis, and probed with [32P]cDNA representing the total mouse mitochondrial genome. Four major bands were visualized (Fig. 2) and densitometrically quantified on autoradiographs (Table VI) . The bands were identified based on the migration on the agarose gel (33) . Bands A (containing a precursor mRNA corresponding to the ND5/ND6/cytochrome b region of the mitochondrial genome) and B (containing a precursor mRNA corresponding to the ND5/ND6 region of the mitochondrial genome) were 3 and 10 times increased, respectively, in the RNA preparations from control and HCCLtreated animals. Band C (composed of mitochondrial 16S rRNA, and a precursor mRNA fragment corresponding to the (39) , consistent with the characteristics of the HCCL-treated rat reported here. Based on the recovery of mitochondrial enzymes, the average increase of mitochondrial protein per gram liver induced by HCCL treatment was 21% after 2-3 wk and 39% after 5-6 wk oftreatment. The 39% increase in mitochondrial protein after 5-6 wk of HCCL treatment is in accord with the 45% and 49% increase in CO2 production from pyruvate and palmitate, respectively, by isolated hepatocytes. The HCCL-induced mitochondrial proliferation is similar to that reported for other inducers like valproate (40) accumulation of unusual acyl-CoAs. In contrast to clofibrate, which stimulates not only mitochondrial (41) , but also peroxisomal biogenesis (28, 42) , treatment with HCCL did not induce hepatic peroxisomal proliferation, as shown by equal activities of the two peroxisomal markers catalase and cyanideinsensitive palmitoyl-CoA oxidation in control and HCCL-treated rats expressed per gram liver (Table V) . The lack of peroxisomal proliferation in HCCL-treated animals indicates that mitochondrial and peroxisomal biogenesis can be stimulated by independent mechanisms. While peroxisomes can oxidize long chain fatty acids (42) , the lack of increase in cyanide-insensitive palmitoyl-CoA oxidation with HCCL treatment excludes peroxisomal fl-oxidation as responsible for the increased palmitate oxidation in hepatocytes from HCCL-treated animals. The underlying mechanism of an increased mitochondrial content can be enhanced synthesis of mitochondria, reduced breakdown, or a combination of both. The current studies show that HCCL treatment induces a 3-10-fold increase in precursor mitochondrial mRNA from the ND5/ND6/cytochrome b region of the mitochondrial genome. Since synthesis has been suggested to be the regulating factor for the steady-state levels of rat liver mitochondrial mRNA (43), increased mRNA levels are consistent with an enhanced transcription of the mitochondrial genome. Another explanation for these findings may be a defect in processing of mitochondrial mRNA in HCCL-treated animals, since the bands visualized on the Northern blots represent mRNA precursors and not mRNA coding for a single mitochondrial protein. In hyperthyroid rats, a well-characterized animal model of hepatic mitochondrial proliferation (44) , the same qualitative changes in the mitochondrial RNA pattern including preferential accumulation of precursor mRNAs, have been described as in the present investigation (45) . The changes are consistent with enhanced mitochondrial synthesis as a mechanism that increases mitochondrial content in the HCCL-treated rat.
Mitochondrial proliferation may be a mechanism to counteract the inhibitory effect of accumulated acyl-CoAs on mitochondrial metabolism in order to maintain hepatocellular function. An increase in tissue mitochondrial content may be an important feature of cellular response to metabolic disease, and has also been observed in defects of the respiratory chain in humans (46) (47) (48) . Another mechanism described in rats with cobalamin deficiency-induced methylmalonic aciduria is a higher CoA content per gram liver (4, 15). Both mechanisms develop over a period of weeks in vivo and can therefore not prevent acute toxicity due to hepatocellular buildup of pro-pionyl-CoA and methylmalonyl-CoA (9) (10) (11) (12) (13) (14) . During chronic accretion of acyl-CoAs induced by treatment with HCCL over 5 wk, however, these compensatory mechanisms may contribute to the relatively normal fuel homeostasis in these animals (4).
In conclusion, the present study shows that HCCL-induced methylmalonic aciduria is associated with increased hepatic mitochondrial capacity. This enhanced mitochondrial capacity may be a compensatory mechanism to maintain hepatocellular function in the presence of high intramitochondrial concentrations of toxic acyl-CoAs. The HCCL-treated rat provides a useful model for studying cellular responses in vivo and in vitro to a specific metabolic defect analogous to the defect in the human hereditary methylmalonic acidurias.
